The Weekly Summary

August 6th – August 11th                                 2018

In general news, President Trump reinstated sanctions against Iran, as that economy teeters, and dealt a blow to the faltering Turkish economy with sanctions in retaliation for Turkey holding an American prisoner. In the U.S., severe weather dominated the news, with Armageddon scenes of massive fires and “fire-nados” all over California, storms in the Midwest, and floods in the East.

In healthcare business news, the AMA opposed the planned merger of CVS and Aetna (AET). Regeneron (REGN) and Bluebird (BLUE) partnered on drug development.

On the data front, Protagonist (PTGX) shares spiked on data for PTG-100 to treat IBD. Spark (ONCE) shares fell on bad data for hemophilia A gene therapy. Ovid (OVID) fell on bad OV101 data to treat Angelam Syndrome. Bellerophon (BLPH) fell on bad data for INOpulse to treat PAH. Finally, Ampio (AMPE) imploded on bad data for Ampion

From the FDA, Alnylam’s (ALNY) received approval for gene-silencing therapy Onpattro to treat orphan disease polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Pain (PTIE) shares fell when the agency rejected extended-release oxycodone Remoxy. Finally, the first drug to be approved for the new “Competitive Generic Therapy” designation was private Apotex’s potassium chloride.

This entry was posted in - The Weekly Summary. Bookmark the permalink.

Leave a Reply

Your email address will not be published.